Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker

开始日期2025-06-01

申办/合作机构

Ain Shams University

NCT06960694

/ Not yet recruiting临床2期IIT

Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial

The purpose of this study is to evaluate the effects of L-carnitine on symptomatic improvement, oxidative stress, and inflammation in mild to moderate knee osteoarthritis patients.

开始日期2025-05-01

申办/合作机构

Bangabandhu Sheikh Mujib Medical University

NCT03994874

/ Recruiting临床1/2期

Peritoneal Ultrafiltration in Cardio Renal Syndrome to Prevent Heart Failure Exacerbation.

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

开始日期2025-04-16

申办/合作机构

Iperboreal Pharma Srl

100 项与左卡尼汀相关的临床结果

登录后查看更多信息

100 项与左卡尼汀相关的转化医学

登录后查看更多信息

100 项与左卡尼汀相关的专利（医药）

登录后查看更多信息

15,389

项与左卡尼汀相关的文献（医药）

2025-12-31·GYNECOLOGICAL ENDOCRINOLOGY

Improved insulin sensitivity and reproductive profile in overweight/obese PCOS patients undergoing integrative treatment with carnitines, L-arginine, L-cysteine and myo-inositol

Article

作者: Rusce, Maria Laura ; Spelta, Eleonora ; Battipaglia, Christian ; Genazzani, Alessandro D. ; Foschi, Martina ; Kostrzak, Anna ; Szeliga, Anna ; Meczekalski, Blazej ; Aio, Claudia ; Semprini, Elisa

OBJECTIVE:

To evaluate the effects of a combination of carnitines, L-arginine, L-cysteine and myo-inositol on metabolic and reproductive parameters in PCOS overweight/obese patients.

METHODS:

This was a retrospective study analyzing information of a group of PCOS (n = 25) overweight/obesity patients, not requiring hormonal treatment, selected from the database of the ambulatory clinic of the Gynecological Endocrinology Center at the University of Modena and Reggio Emilia, Modena, Italy. The hormonal profile, routine exams and insulin and C-peptide response to oral glucose tolerance test (OGTT) were evaluated before and after 12 weeks of a daily oral complementary treatment with L-carnitine (500 mg), acetyl-L-carnitine (250 mg), L-arginine (500 mg), L-cysteine (100 mg) and myo-inositol (1 gr). The hepatic insulin extraction index was also calculated.

RESULTS:

The mix of complementary substances significantly improved metabolic parameters, homeostatic model assessment for insulin resistance index values and gonadotropin plasma levels. Glucose, C-peptide and insulin response to OGTT was significantly reduced as well as the hepatic insulin extraction index.

CONCLUSION:

The administration of a combination of carnitines, L-arginine, L-cysteine and myoinositol improved gonadotropin plasma levels and insulin sensitivity in overweight/obese PCOS patients and restored hepatic clearance of insulin as demonstrated by the decreased hepatic insulin extraction index.

2025-12-31·Gut Microbes

Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition

Article

作者: Wang, Jin-Town ; Lo, Yi-Ling ; Kuo, Han-Chun ; Kao, Hsien-Li ; Hsu, Chia-Lang ; Yen, Jeffrey J Y ; Sheen, Lee-Yan ; Chen, Yi-Hsun ; Hsu, Cheng-Chih ; Liao, Yu-Chieh ; Panyod, Suraphan ; Lo, I-Hsuan ; Kuo, Ching-Hua ; Chiu, Tina H T ; Zou, Hsin-Bai ; Yang, Yu-Tang ; Chiu, Jian-Ying ; Chuang, Hsiao-Li ; Wu, Ming-Shiang ; Wu, Wei-Kai ; Chiu, Han-Mo

Gut microbial metabolism of L-carnitine, which leads to the production of detrimental trimethylamine N-oxide (TMAO), offers a plausible link between red meat consumption and cardiovascular risks. Several microbial genes, including cntA/B, the cai operon, and the recently identified gbu gene cluster, have been implicated in the conversion of dietary L-carnitine into TMA(O). However, the key microbial genes and associated gut microbes involved in this pathway have not been fully explored. Utilizing the oral carnitine challenge test (OCCT), which specifically measures TMAO production from L-carnitine intake and identifies TMAO producer phenotypes, we compared the abundance of microbial genes between low- and high-TMAO producers across three independent cohorts. Our findings consistently revealed that the gbu gene cluster, rather than cntA/B or the cai operon, was significantly enriched in high-TMAO producers. We further analyzed 292 paired multi-omic datasets from OCCT and shotgun metagenomic sequencing, which demonstrated a significant positive correlation between the abundance of fecal gbu genes and L-carnitine-induced TMAO production, with gbuB showing the strongest correlation. Interestingly, these fecal gbu genes were found to increase with L-carnitine supplementation and decrease with a plant-based diet. Notably, we verified a previously uncultured gbu-containing bacterium, JAGTTR01 sp018223385, as the major contributor to TMA formation in the human gut. We isolated these gbu-containing gut microbes and confirmed their role in TMA/TMAO production using anaerobic incubation and a gnotobiotic mouse model. Using an in-house collection of gbu-containing isolates, we developed a qPCR-based method to quantify fecal gbuB and validated its correlation with L-carnitine-mediated TMAO production as measured by OCCT. Overall, these findings suggest that gbu-containing gut microbes are crucial for TMAO increases following L-carnitine intake and may serve as biomarkers or targets for personalized nutrition.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

作者: Saseen, Joseph J. ; Dardouri, Mouna ; Nair, Kavita V. ; Moore, Gina D. ; DiStefano, Michael J.

Background:

High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.

Methods:

We conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.

Results:

We identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.

Conclusion:

This study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

200

项与左卡尼汀相关的新闻（医药）

2025-07-01

·PRNewswire

NEW STUDY SHOWS SNACKING ON MIXED TREE NUTS MAY IMPACT CARDIOVASCULAR RISK FACTOR TMAO

New Findings Published in Nutrients in Partnership with the International Tree Nut Council Nutrition Research & Education Foundation DAVIS, Calif., July 1, 2025 /PRNewswire/ -- In a paper1 published online this week in the journal, Nutrients, researchers found that consuming mixed tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) in a hypocaloric diet resulted in reduced body weight and plasma levels of the cardiovascular risk factor trimethylamine N-oxide (TMAO). The decrease in TMAO levels was greatest among individuals with lower-quality baseline diets. In a previous study2, researchers at UCLA demonstrated that consuming 1.5 ounces of tree nuts per day (versus pretzels) during 24 weeks of weight loss and weight maintenance, resulted in weight loss, and decreased blood pressure and heart rate—signs of reduced cardiovascular risk. TMAO, a gut microbiome metabolite, is a novel cardiovascular disease risk factor. It is produced by the liver from trimethylamine (TMA), which is generated by gut bacteria from dietary precursors such as choline, phosphatidylcholine and L-carnitine. Diet can impact TMAO levels by modifying the gut microbiota, effecting the production of TMA from nutrients like choline and L-carnitine. Tree nuts, which are rich in phytochemicals such as carotenoids, phenolic acids and phytosterols, may also affect TMAO production. The current study looked at whether tree nut snacks, as part of a hypocaloric diet, could influence TMAO levels and their relationship with the gut microbiome. Plasma samples were collected and evaluated from 95 overweight or obese participants. Nutritional data were collected at baseline and week 12 via dietary recall. Each study participant was given a Healthy Eating Index (HEI) score, which is used to assess diet quality based on the Dietary Guidelines or Americans. According to lead researcher, Zhaoping Li, MD, PhD, Professor of Medicine and Chief of the Division of Clinical Nutrition at UCLA, "While the hypocaloric diet with tree nuts and pretzels both resulted in a significant reduction in plasma TMAO levels, the reduction of TMAO was more profound in those consuming mixed tree nuts with poor dietary habits and low HEI scores." Interestingly, the dietary intervention did not significantly alter the intake of dietary sources of TMAO, including choline and phosphatidylcholine. Therefore, the observed decrease in TMAO plasma levels is unlikely due to a reduction in TMAO precursors. "Adding mixed tree nuts to hypocaloric diets may not only help in the reduction of plasma TMAO levels, but may be an important intervention for managing cardiovascular health," stated Dr. Li. In support of these findings, Maureen Ternus, M.S., R.D., Executive Director of the International Tree Nut Council Nutrition Research & Education Foundation (INC NREF), emphasized, "This study is yet another piece of evidence showing that people should include more nuts in their diet. Just a handful of tree nuts (1.5 ounces or 1/3 cup) every day can result in numerous health benefits." The International Tree Nut Council Nutrition Research & Education Foundation (INC NREF) is a non-profit, non-governmental organization dedicated to supporting nutrition research and education for consumers and health professionals throughout the world. Members include those associations and organizations that represent the nine tree nuts (almonds, Brazils, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts). For more information, please visit our website at . 1 Lei, O., J. Yang, H.H. Kang, Z. Li., 2025. Impact of a 12-week hypocaloric weight loss diet with mixed tree nuts vs. pretzels on trimethylamine-n-oxide (TMAO) levels in overweight adults. Nutrients 17(13): 2137. 2 Wang, J., S. Wang, S.M., Henning, T. Qin, Y. Pan, J. Yang, J. Huang, C.-H. Tseng, D. Heber, Z. Li., 2021 Mixed tree nut snacks compared to refined carbohydrate snacks resulted in weight loss and increased satiety during both weight loss and weight maintenance: a 24-week randomized controlled trial. Nutrients. 13(5), 1512. SOURCE International Tree Nut Council Nutrition Research & Education Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果

2025-06-27

·米内网

南京正大天晴大丰收！手握13个亿级产品，领跑3大百亿市场，6款新药、10个首仿药来袭

精彩内容近日，南京正大天晴制药首家申报西达本胺片仿制上市备受市场瞩目，公司近8年已陆续拿下12个首仿药，成绩亮眼。2024年在中国公立医疗机构终端，南京正大天晴制药有13个产品销售额超过1亿元，在9个亚类市场挺进TOP20企业之列，市场优势明显。公司坚持“以仿制带动创新，以创新驱动未来”的研发理念，目前已布局了6款新药，10个高端仿制药将冲刺国内首仿。领跑3大百亿市场，13个重磅产品卖过亿资料显示，南京正大天晴制药成立于2001年，历经了二十余载的耕耘，已发展为以药物研发及生产为主体，原料药平台、商业平台为两翼全产业链格局的国内明星药企。公司产品涵盖心脑血管、肿瘤、影像、外科围术、消化、泌尿等治疗领域，米内网数据显示，截至目前南京正大天晴制药已上市的化学药和中成药合计超过80个（按产品名统计）。2024年在中国公立医疗机构终端（城市公立医院+县级公立医院+城市社区中心+乡镇卫生院），南京正大天晴制药在9个亚类市场挺进TOP20企业之列，公司13个重磅产品销售额超过1亿元。高血压用药2024年在中国公立医疗机构终端的销售规模在450亿元以上，南京正大天晴制药升上TOP8企业，近四年销售额保持稳定增长。公司畅销的高血压用药包括了厄贝沙坦氢氯噻嗪片、奥美沙坦酯氨氯地平片、托伐普坦片等。图1：近五年南京正大天晴制药的高血压用药销售情况（单位：万元）来源：米内网中国公立医疗机构终端竞争格局血脂调节剂（化+生）2024年在中国公立医疗机构终端的销售规模在170亿元以上，南京正大天晴制药排在TOP15企业，近两年增速达双位数。公司畅销的血脂调节剂包括了瑞舒伐他汀钙片、氨氯地平阿托伐他汀钙片。造影剂（化+生）2024年在中国公立医疗机构终端的销售规模在150亿元以上，南京正大天晴制药排在TOP9企业。公司畅销的造影剂包括了碘克沙醇注射液、碘帕醇注射液。一般营养品2024年在中国公立医疗机构终端的销售规模达95亿元，南京正大天晴制药排在TOP14企业。公司畅销的一般营养品有木糖醇注射液。影响骨结构及其矿化的药物（化+生）2024年在中国公立医疗机构终端的销售规模超过60亿元，南京正大天晴制药排在TOP12企业。公司畅销的影响骨结构及其矿化的药物有帕米膦酸二钠葡萄糖注射液。止吐药和止恶心药2024年在中国公立医疗机构终端的销售规模也超过了60亿元，南京正大天晴制药排在TOP9企业，近四年销售额保持稳步增长。公司畅销的止吐药和止恶心药包括了阿瑞匹坦胶囊、盐酸阿扎司琼氯化钠注射液、盐酸阿扎司琼注射液。图2：近五年南京正大天晴制药的止吐药和止恶心药销售情况（单位：万元）来源：米内网中国公立医疗机构终端竞争格局此外，南京正大天晴制药还是中成药前列腺用药TOP15企业、治疗痔疮和肛裂的药物TOP1企业、性功能障碍类药物TOP6企业。表1：2024年南京正大天晴制药在中国公立医疗机构终端销售额过亿的产品来源：米内网中国公立医疗机构终端竞争格局厄贝沙坦氢氯噻嗪片是南京正大天晴制药最畅销的产品，2021-2024年在中国公立医疗机构终端的销售额保持在6亿元以上。注射用盐酸伊达比星是公司在2020年获批的产品，2021-2024在中国公立医疗机构终端连续增长了2834%、60%、15%、8%，销售额在2024年涨至1.4亿元，已跃升为公司第二畅销的抗肿瘤药。托伐普坦片是公司在2021年获批的产品，2022-2024在中国公立医疗机构终端连续增长了927%、115%、42%，销售额在2024年突破1亿元，不仅是公司新的过亿产品，也是公司第三畅销的高血压用药。6款新药如火如荼，1900亿生物药市场将迎新突破近年来，在政策赋能与技术创新的双轮驱动下，中国生物药市场加速扩容，2018年在中国公立医疗机构终端生物药的销售规模突破1000亿元，2024年逼近1964亿元，到了2025年或将突破2000亿元。截至目前，南京正大天晴制药暂无生物药获批，但近几年公司在积极布局化药新药的同时，触角也伸到了生物药领域。图3：南京正大天晴制药申报的生物药新药来源：米内网中国申报进度（MED）数据库2023年1月，南京正大天晴制药首家提交了艾美赛珠单抗注射液3.3类新药临床申请，随后在2025年5月再提交了两个受理号的临床申请。艾美赛珠单抗注射液是罗氏的重磅止血药，2024年全球销售额超过45亿瑞士法郎（按即时汇率换算约56亿美元），在中国公立医疗机构终端止血药市场为TOP11产品。2025年5月，南京正大天晴制药首个生物药1类新药NTB003注射液获批临床，用于甲状腺眼病(TED)的治疗，该新药也是公司是眼科用药市场首个布局的产品。表2：南京正大天晴制药在研的化药新药来源：米内网中国临床试验数据库2021年起，南京正大天晴制药陆续提交了4款化药1类新药的临床申请，目前已全部获得了临床批件。其中进度最快的是NTQ5082胶囊，阵发性睡眠性血红蛋白尿症的II期临床在2024年年底启动，而另一个适应症原发性IgA肾病的II期临床在2025年5月启动。此外，NTQ3617片也在今年1月启动了晚期实体瘤的I期临床。南京正大天晴制药布局的化药新药集中在抗肿瘤和免疫调节领域，2024年在中国公立医疗机构终端抗肿瘤和免疫调节剂化药（不含生物药）的市场规模在1100亿元以上。“首仿药大户”出击！八年拿下12个，10款在冲刺2018年以来，南京正大天晴制药进入了新品丰收期，至今已累计获批了49个新产品，均为仿制药，其中12个是首仿药（含同日获批），公司的抢仿实力在业内名列前茅。表3：南京正大天晴制药2018年至今获批的首仿药注：上述首仿药指按仿制上市申请并首家获批的产品来源：米内网中国申报进度（MED）数据库芦比前列酮软胶囊目前为独家产品，南京正大天晴制药在2023年6月拿下国内首仿+首家过评，该产品在中国公立医疗机构终端2023年Q3+Q4的销售额为12万元，2024年全年涨至2961万元，米内网最新数据显示，2025年Q1也收获了1679万元，该产品正在快速释放市场潜力。表4：南京正大天晴制药报产在审的新品来源：米内网中国申报进度（MED）数据库截至2025年6月26日，南京正大天晴制药报产在审的新品有19个，均为仿制药，其中氘丁苯那嗪片、奥贝胆酸片、苯磺酸美洛加巴林片、甲磺酸沙非胺片、八氟丙烷脂质微球注射液、蔗糖羟基氧化铁咀嚼片、亚甲蓝肠溶缓释片、左卡尼汀咀嚼片、佩玛贝特片、西达本胺片10个产品暂无国产仿制药获批，公司的首仿药梯队有望新添多个产品，值得期待。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至6月26日，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

2025-06-22

·信狐药迅

康希诺-国产13价肺炎球菌多糖结合疫苗上市| 新获批(6.16-6.22）

每周药品注册获批数据，分门别类呈现，一目了然。(6.16-6.22）新药上市申请药品名称企业注册分类受理号13价肺炎球菌多糖结合疫苗(CRM197,TT载体)康希诺生物股份公司2.2CXSS2400020新药临床申请药品名称企业注册分类受理号HRS-8829注射用浓溶液北京盛迪医药有限公司1CXHL2500379艾本那肽注射液常山凯捷健生物药物研发(河北)有限公司1CXHL2500378注射用TFX05-01浙江扬厉医药技术有限公司1CXHL2500373TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500371TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500370DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500376DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500375DAT-1604片北京丹擎医药科技有限公司1CXHL2500364DAT-1604片北京丹擎医药科技有限公司1CXHL2500363WEYZ-1乳膏南京韦尔优众医药有限公司1CXHL2500365177Lu-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL250035968Ga-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL2500358VCT220片成都闻泰医药科技有限公司1CXHL2500355VCT220片成都闻泰医药科技有限公司1CXHL2500354VCT220片成都闻泰医药科技有限公司1CXHL2500353AOD113408注射液成都奥达生物科技有限公司1CXHL2500339EDP167注射液亿腾医药(珠海)有限公司1CXHL2500336JKN2301干混悬剂健康元药业集团股份有限公司1CXHL2500327EP-0203XR成都苑东生物制药股份有限公司2.3CXHL2500333舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500374枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500351枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500350枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500349枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500348ZHCX002九华华源药业股份有限公司2.4CXHL2500313流感病毒裂解疫苗(BK-01佐剂)长春百克生物科技股份公司3.2CXSL2500239SCTB39-1注射液神州细胞工程有限公司1CXSL2500364AI-081注射液南京昂科免疫生物医药有限公司1CXSL2500304PM1300注射用冻干制剂珠海普米斯生物科技有限公司1CXSL2500290注射用HY0001a四川汇宇海玥医药科技有限公司1CXSL2500294LNF2102注射液山东新时代药业有限公司1CXSL2500287注射用QLS32015齐鲁制药有限公司1CXSL2500285注射用LY4101174礼来苏州制药有限公司1CXSL2500272注射用ZG006苏州泽璟生物制药股份有限公司1CXSL2500279注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2500278CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2500275ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500264ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500263IMC-003宜明凯尔生物医药技术(上海)有限公司1CXSL2500261HD006细胞华道(上海)生物医药有限公司1CXSL2500251QL2109注射液齐鲁制药有限公司2.2CXSL2500284仿制药申请药品名称企业注册分类受理号盐酸苯海拉明注射液华夏生生药业(北京)有限公司3CYHS2501576复方电解质注射液(V)河北天成药业股份有限公司3CYHS2400745法莫替丁注射液海南全星制药有限公司3CYHS2400674氯化钙注射液华夏生生药业(北京)有限公司3CYHS2400602尼麦角林片浙江赛默制药有限公司3CYHS2400518己酮可可碱注射液辰欣药业股份有限公司3CYHS2400498法莫替丁注射液东阳祥昇医药科技有限公司3CYHS2400342美洛昔康注射液石药集团中诺药业(石家庄)有限公司3CYHS2400303阿奇霉素颗粒重庆莱美药业股份有限公司3CYHS2400199盐酸西替利嗪口服溶液福建海西新药创制股份有限公司3CYHS2303555注射用盐酸罗沙替丁醋酸酯山东豪瑞恩制药有限公司3CYHS2303400醋酸葡萄糖维持液仁合益康集团有限公司3CYHS2303177醋酸葡萄糖维持液仁合益康集团有限公司3CYHS2303176布洛芬注射液陕西丽彩药业有限公司3CYHS2303063布洛芬注射液陕西丽彩药业有限公司3CYHS2303062重酒石酸间羟胺注射液弘和制药有限公司3CYHS2302971硫辛酸片浙江恒研医药科技有限公司3CYHS2302913醋酸钙片青岛百洋制药有限公司3CYHS2302887地氯雷他定口服溶液湖南嘉恒制药有限公司3CYHS2302849己酮可可碱注射液浙江北生药业汉生制药有限公司3CYHS2302843异烟肼注射液海南秋实医药科技有限公司3CYHS2302710氨溴特罗口服溶液南京易腾药物研究院有限公司3CYHS2302510磷酸奥司他韦干混悬剂恒昌(广州)新药研究有限公司3CYHS2302257地塞米松磷酸钠注射液汇禹远和(海南)药业有限公司3CYHS2300998枸橼酸铋钾片浙江京新药业股份有限公司4CYHS2402389非诺贝特酸胆碱缓释胶囊湖南九典制药股份有限公司4CYHS2401389阿司匹林肠溶片浙江易泽达医药科技有限公司4CYHS2401356贝前列素钠片山东百诺医药股份有限公司4CYHS2401345达肝素钠注射液辰欣药业股份有限公司4CYHS2401232达肝素钠注射液辰欣药业股份有限公司4CYHS2401231盐酸达泊西汀片浙江北生药业汉生制药有限公司4CYHS2400915盐酸达泊西汀片昆山培力药品有限公司4CYHS2400863复方托吡卡胺滴眼液山东辰欣佛都药业股份有限公司4CYHS2400860盐酸氨溴索口服溶液黑龙江澳利达奈德制药有限公司4CYHS2400828甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400815甲氨蝶呤注射液江苏奥赛康药业有限公司4CYHS2400814比索洛尔氨氯地平片天大药业(珠海)有限公司4CYHS2400634丙酸氟替卡松乳膏重庆华邦制药有限公司4CYHS2400596夫西地酸乳膏重庆华邦制药有限公司4CYHS2400560注射用唑来膦酸浓溶液广州市联瑞制药有限公司4CYHS2400505盐酸达泊西汀片郑州德迈药业有限公司4CYHS2400522注射用硫酸艾沙康唑山西德元堂药业有限公司4CYHS2400392盐酸氨溴索口服溶液湖北凯纳药业有限公司4CYHS2400216盐酸氨溴索口服溶液湖北凯纳药业有限公司4CYHS2400215磷霉素氨丁三醇颗粒苏州二叶制药有限公司4CYHS2400128西甲硅油乳剂成都倍特得诺药业有限公司4CYHS2400109布洛芬混悬液河南省尤里卡生物科技有限公司4CYHS2400070布洛芬混悬液河南省尤里卡生物科技有限公司4CYHS2400069瑞巴派特片东阳祥昇医药科技有限公司4CYHS2400078蒙脱石散郑州泰丰制药有限公司4CYHS2303493铝碳酸镁咀嚼片太康海恩药业有限公司4CYHS2303433他氟前列素滴眼液江苏安必生制药有限公司4CYHS2303258吸入用布地奈德混悬液江苏西普拉制药有限公司4CYHS2303217富马酸伏诺拉生片宁波科尔康美诺华药业有限公司4CYHS2303018富马酸伏诺拉生片宁波科尔康美诺华药业有限公司4CYHS2303017布南色林片河北龙海药业有限公司4CYHS2302617左卡尼汀口服溶液吉林省辉南长龙生化药业股份有限公司4CYHS2301985唑来膦酸注射液吉林四长制药有限公司4CYHS2300987盐酸乌拉地尔注射液北京民康百草医药科技有限公司4CYHS2300535四价流感病毒裂解疫苗复星雅立峰(大连)生物制药有限公司3.3CXSS2200083利妥昔单抗注射液山东新时代药业有限公司3.3CXSS2400015达普司他片齐鲁制药(海南)有限公司3CYHL2500085达普司他片齐鲁制药(海南)有限公司3CYHL2500084达普司他片齐鲁制药(海南)有限公司3CYHL2500083达普司他片齐鲁制药(海南)有限公司3CYHL2500082镥[177Lu]氧奥曲肽注射液迈得诺医疗科技集团有限公司3CYHL2500076盐酸达克罗宁局部溶液剂深圳珐玛易药品科技有限公司3CYHL2500073沙美特罗替卡松吸入粉雾剂杭州知兴制药有限公司4CYHL2500068吸附破伤风疫苗北京智飞绿竹生物制药有限公司3.3CXSL2500250流感病毒裂解疫苗陕西昆秦生物科技有限公司3.3CXSL2500243人生长激素注射液亿帆医药(上海)有限公司3.3CXSL2500289进口申请药品名称企业注册分类受理号盐酸达利雷生片Idorsia Pharmaceuticals Deutschland GmbH5.1JXHS2400050盐酸达利雷生片Idorsia Pharmaceuticals Deutschland GmbH5.1JXHS2400049左甲状腺素钠片Aristo Pharma GmbH5.2JYHS2400034左甲状腺素钠片Aristo Pharma GmbH5.2JYHS2400033重酒石酸间羟胺注射液Wockhardt Bio Pty Ltd.5.2JYHS2400006注射用醋酸卡泊芬净Gland Pharma Limited5.2JYHS2300034骨化三醇软胶囊Strides Pharma Global Pte Limited5.2JYHS2200010国;JYHS2200010骨化三醇软胶囊Strides Pharma Global Pte Limited5.2JYHS2200009国;JYHS2200009Casdatifan 片Arcus Biosciences, Inc.1JXHL2500076奥拉帕利片AstraZeneca AB2.4JXHL2500083奥拉帕利片AstraZeneca AB2.4JXHL2500082ABBV-324注射用粉末AbbVie Inc.1JXSL2500055MEDI5752AstraZeneca AB1JXSL2500056Isatuximab注射液(皮下注射)Sanofi-Aventis Recherche & Développement2.1JXSL2500053Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500052Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500051中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗申请上市上市批准

100 项与左卡尼汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02176	左卡尼汀	A16AA01	DB00583

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾脏疾病	意大利	Alfasigma SpA	2015-05-18
脓毒性休克	意大利	Alfasigma SpA	2015-05-18
心血管疾病	中国	Leadiant Biosciences, Inc.	1999-12-31
遗传性代谢缺陷病	爱尔兰	Shire Pharmaceutical Development Ltd.	1996-10-23
肉毒碱棕榈酰转移酶缺乏症	荷兰	Sigma-Tau Industrie Farmaceutiche Riunite SpA	1986-02-03
全身性肉碱缺乏症	美国	Leadiant Biosciences, Inc.	1985-12-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
炎症	临床3期	埃及	Tanta University	2023-03-05
疼痛	临床3期	埃及	Tanta University	2023-03-05
类风湿关节炎	临床3期	埃及	Tanta University	2023-03-05
中度持续性哮喘	临床3期	埃及	Tanta University	2022-08-08
持续性哮喘	临床3期	埃及	Tanta University	2022-08-08
β地中海贫血	临床3期	埃及	Tanta University	2022-07-08
难治性心力衰竭	临床3期	中国	李氏大药厂控股有限公司	2011-01-01
I型脊髓性肌萎缩症	临床2期	美国	Leadiant Biosciences, Inc.	2008-04-01
I型脊髓性肌萎缩症	临床2期	加拿大	Leadiant Biosciences, Inc.	2008-04-01
I型脊髓性肌萎缩症	临床2期	德国	Leadiant Biosciences, Inc.	2008-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISN WCN2024	N/A	L-carnitine \| levocarnitine	284	L-carnitine supplementation	築鬱淵淵餘網糧壓鬱範(窪選淵壓餘範築鹽夢選) = 醖積衊簾願窪繭觸膚襯築顧簾網鬱遞夢壓觸獵 (構餘顧齋膚築齋遞蓋積, -10.29 ~ 4.13) 更多	不佳	2024-04-01
NCT05083637 (Pubmed \| J Nutr)	N/A	营养不良 Myeloperoxidase \| Neopterin \| alpha-1-antitrypsin ... 更多	98	L-carnitine syrup (100 mg/kg/d)	廠糧選壓鹹糧襯鑰鏇憲(壓顧夢醖廠壓廠蓋夢願) = 網糧選膚積廠蓋繭齋鹽糧鏇齋齋觸窪範鏇遞憲 (觸構觸衊夢鏇襯鏇繭壓, -556.58 ~ 249.91)	不佳	2024-03-01
AASLD2023	N/A	肝性脑病 \| 高氨血症	-	Oral L-Carnitine	醖製鹽獵獵網顧衊夢願(壓膚選膚鹽觸構遞衊鹽) = 窪簾襯壓範鹹憲餘窪衊製窪觸積鹹製壓憲顧齋 (鹹築艱製膚窪膚網願餘 ) 更多	-	2023-11-10
ATS2023	N/A	脑疾病	-	Valproate	夢繭齋願鹹憲淵糧夢觸(餘艱製鹹選製鑰鹹築膚) = hemodynamic instability, metabolic derangements, encephalopathy, and cerebral edema that can progress to coma and death 繭艱選顧淵艱範網艱窪 (遞簾襯鏇鏇鏇構鹹選簾 ) 更多	-	2023-05-21
ESMO2022	N/A	头颈部肿瘤	150	L-carnitine 500mg	淵夢繭範鑰廠鑰網範艱(襯鹽鑰顧鹹積蓋鬱壓憲) = 簾積構製蓋簾遞獵鬱觸壓鏇窪簾蓋窪鹹衊觸醖 (構觸糧憲築構壓鬱遞鬱 )	-	2022-09-10
ESMO2022	N/A	头颈部肿瘤	150	L-carnitine (Control)	淵夢繭範鑰廠鑰網範艱(襯鹽鑰顧鹹積蓋鬱壓憲) = 觸範鑰鬱糧積選選鑰艱壓鏇窪簾蓋窪鹹衊觸醖 (構觸糧憲築構壓鬱遞鬱 )	-	2022-09-10
NCT01783041 (CTgov)	临床2/3期	全身性肉碱缺乏症 \| 早产 \| 神经发育障碍	144	5% Dextrose (5% Dextrose)	窪窪鹽積選壓製選壓製(鹽觸鑰繭糧遞繭醖艱範) = 範淵鹹蓋壓廠顧築艱獵製膚獵壓遞憲繭淵鹹鏇 (鏇蓋醖膚顧繭網廠選糧, 3.5) 更多	-	2022-03-08
NCT01783041 (CTgov)	临床2/3期	全身性肉碱缺乏症 \| 早产 \| 神经发育障碍	144	L-carnitine (L-carnitine)	窪窪鹽積選壓製選壓製(鹽觸鑰繭糧遞繭醖艱範) = 鏇獵鑰淵艱廠鬱憲鬱鑰製膚獵壓遞憲繭淵鹹鏇 (鏇蓋醖膚顧繭網廠選糧, 3.3) 更多	-	2022-03-08
ESC2021	N/A	电流引起烧伤 KCNH2-N588K	-	L-Carnitine	構願淵遞積醖衊襯網鹽(壓鹽築廠積醖鏇餘醖齋) = 鏇築廠艱遞膚衊醖構繭遞膚淵壓積獵鹽積窪憲 (衊觸壓餘鑰鏇壓憲壓壓 ) 更多	-	2021-08-29
ESC2021	N/A	电流引起烧伤 KCNH2-N588K	-	L-Carnitine	構願淵遞積醖衊襯網鹽(壓鹽築廠積醖鏇餘醖齋) = 糧餘製選醖糧醖獵齋夢遞膚淵壓積獵鹽積窪憲 (衊觸壓餘鑰鏇壓憲壓壓 )	-	2021-08-29
NCT03426722 (Pubmed \| Invest New Drugs)	临床3期	胃肠道间质瘤一线	42	L-carnitine	獵獵鬱範壓鏇餘醖鏇範(構壓願壓齋蓋窪餘鏇積) = 廠鏇衊鹽繭艱構選艱艱遞製淵蓋醖願襯齋糧鏇 (鏇蓋艱顧艱構遞餘觸鹽 ) 更多	-	2020-04-01
IC 172 (ASN2019)	N/A	霍奇金淋巴瘤维持	172	Intravenous L-Carnitine (LC) 1000 mg	淵窪夢淵積選鬱壓範衊(壓遞蓋淵鏇鏇壓願壓糧) = 鑰衊襯糧獵餘醖餘襯餘齋獵網鏇艱簾醖網鏇鹽 (製壓齋鏇膚壓鬱鬱廠醖 )	积极	2019-11-05
ASN2019	N/A	腹膜透析并发症 serum free carnitine (FC) \| acyl-carnitine (AC) \| urinary L-FABP ... 更多	24	L-carnitine supplementation (750 mg/day)	鬱襯蓋鏇襯窪願遞襯鬱(鹽蓋窪簾構顧構衊糧顧) = 餘壓繭網壓蓋膚獵廠憲淵蓋襯窪艱願網壓齋網 (糧淵壓艱築淵繭繭鹹齋 ) 更多	积极	2019-11-05
ASN2019	N/A		24	L-Carnitine (Control)	鬱襯蓋鏇襯窪願遞襯鬱(鹽蓋窪簾構顧構衊糧顧) = 醖淵鬱簾願鏇鏇鏇遞遞淵蓋襯窪艱願網壓齋網 (糧淵壓艱築淵繭繭鹹齋 ) 更多	积极	2019-11-05